Stock ABOS ACUMEN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Delayed Nasdaq
Other stock markets
 03:55:54 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.19 USD +0.31% Intraday chart for Acumen Pharmaceuticals, Inc. +0.95% -16.93%
Apr. 04 Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug MT
Apr. 04 Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting
AQ
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
GL
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug
MT
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate
MT
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
GL
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease
CI
Acumen Pharmaceuticals Files $200 Million Mixed Shelf
MT
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Acumen Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
GL
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
GL
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
AQ
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
GL
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
AQ
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
GL
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
AQ
Acumen Pharmaceuticals : ADPD 2024 CSF Biomarker Presentation
PU
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
GL
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABOS Stock
  4. News Acumen Pharmaceuticals, Inc.